Advances in Castration-Sensitive Prostate Cancer: A Pharmacist's Approach to Optimize Novel Antiandrogen Therapies

This activity was originally presented live at the 2025 Oncology Pharmacists Connect Conference in Austin, Texas.

The treatment of castration-sensitive prostate cancer (CSPC) has evolved with the introduction of novel antiandrogens. However, determining the most appropriate treatment requires careful consideration of disease characteristics, patient factors, and drug properties. The session provides a general overview of prostate cancer, its pathophysiology, and screening methods, as well as the principles of androgen deprivation therapy and the role of novel antiandrogens. Oncology pharmacists must have a comprehensive understanding of these agents to support evidence-based prescribing. As the field evolves, oncology pharmacists must adapt to new treatment paradigms and manage potential toxicities effectively to improve patient outcomes, including adherence, and reduce treatment discontinuation rates. This session will delve into current guidelines and the evolving landscape of CSPC treatment, highlighting recent updates from clinical trials and the rationale for doublet versus triplet therapy in CSPC. Critical aspects of managing toxicities, nonadherence, and early discontinuation of these therapies, including strategies for adverse effect prevention, monitoring, and management, as well as essential patient education and counseling points to optimize treatment outcomes, will be discussed.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: July 2, 2025
Expiration date: July 2, 2026

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate the pharmacologic profiles, clinical indications, and safety considerations of second-generation antiandrogen therapies and abiraterone in the treatment of castration-sensitive prostate cancer (CSPC)
• Examine the evolving treatment landscape of CSPC, focusing on current guideline recommendations, emerging research, and innovative therapeutic strategies
• Identify pharmacist-driven strategies for monitoring, managing, and mitigating adverse effects associated with treatment for CSPC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-221-H01-P. The activity is available for CE credit through July 2, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Megan Hinkley, PharmD, MBA, BCOP

Emma J. Jones, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms